RXi Pharmaceuticals, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. deal

RXi acquired patent rights from the foundation to develop and commercialize NeuVax for use in combination with Herceptin trastuzumab and in low-to-intermediate HER2-positive breast cancer patients not eligible for Herceptin treatment. RXi gained NeuVax through its acquisition of Apthera Inc. earlier this year. The vaccine consisting of an immunogenic peptide derived from epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu) and sargramostim is slated to begin a Phase III trial in 1H12 to treat HER2-positive breast cancer. Terms were not disclosed (see BioCentury, April 4). ...